Testing SV001 for Idiopathic Pulmonary Fibrosis
Part of Lungs & breathing clinical trials.
This trial tests a new drug called SV001 to see if it is safe and tolerable for people with idiopathic pulmonary fibrosis (IPF). If you have IPF and meet certain health criteria, this study may help find new treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with idiopathic pulmonary fibrosis (IPF) and your lung function meets study requirements.
- You agree to use effective birth control during the study and for 6 months after the last dose.
- You do not have other significant lung diseases besides IPF.
- You have not had a severe flare-up of IPF in the last 4 months.
- You have not smoked in the last 3 months and are willing to not smoke during the study.
- You have no history of cancer in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BC006 for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. The goal is to see if it can help improve lung function. You may be eligible if you are 40 or older and have a confirmed IPF diagnosis with specific lung test results.
This trial tests a new drug, SB17170, for people with IPF. It aims to see if the drug can help slow down lung damage. You may be eligible if you have a confirmed diagnosis of IPF and meet certain lung function criteria.
This Phase 2 study tests whether an oral medication (INS018_055) can help people with idiopathic pulmonary fibrosis (IPF). You may be a fit if your lung function is in a certain range and your condition is stable.
This trial tests a new drug called TDI01 to see if it helps people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring. You may qualify if you have a confirmed IPF diagnosis and your lung function is stable enough.
This trial tests an inhaled drug called LTI-03 to see if it can help people with idiopathic pulmonary fibrosis (IPF). It may be an option for those with moderate lung function who are stable on their current treatment.
This trial tests a liquid version of the medication nintedanib (AP02) to see if it is safe and works well for people with idiopathic pulmonary fibrosis (IPF). If you have IPF and have not taken nintedanib or pirfenidone recently, you may be able to join.
Hear when a new Idiopathic Pulmonary Fibrosis(IPF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.